BMJ3d
POS0894 ANTI-IL-6 THERAPY EFFECT FOR REFRACTORY JOINT AND SKIN INVOLVEMENT IN SYSTEMIC SCLEROSIS: A REAL-WORLD, SINGLE CENTER EXPERIENCE
Background: Emerging evidence during the last two decades supports a pivotal role of Interleukin 6 (IL-6) in the pathogenesis of Systemic Sclerosis (SSc). Standard immunosuppressive agents are often ...
BMJ3d
Synovial fibroblasts assume distinct functional identities and secrete R-spondin 2 in osteoarthritis
Correspondence to Dr Tristan Maerz, Department of Orthopaedic Surgery, University of Michigan, Ann Arbor, Michigan, USA; tmaerz{at}med.umich.edu Objectives Synovium is acutely affected following joint ...
BMJ3d
How to cope with pathogenic long-lived plasma cells in autoimmune diseases
Deutsches Rheumaforschungszentrum Berlin and Department of Rheumatology, Charité, Universitätsmedizin Berlin, Berlin, Germany Dr B F Hoyer, Deutsches Rheumaforschungszentrum Berlin and Department of ...
BMJ6d
Effect of disease duration and prior disease-modifying antirheumatic drug use on treatment outcomes in patients with rheumatoid arthritis
Objectives To determine if disease duration and number of prior disease-modifying antirheumatic drugs (DMARDs) affect response to therapy in patients with established rheumatoid arthritis (RA).
BMJ7d
Not only synovitis but also tenosynovitis needs to be considered: why it is time to update textbook images of rheumatoid arthritis
Correspondence to Professor Annette van der Helm-van Mil, Rheumatology, Leiden University Medical Center, Leiden 2300 RC, The Netherlands; A.H.M.van_der_Helm{at}lumc.nl Rheumatoid arthritis (RA) is ...
BMJ8d
AB0379 BARICITINIB IN POLYMYALGIA RHEUMATICA AND GIANT CELL ARTERITIS: REPORT OF SIX CASES
Background: Glucocorticoids (GC) are the cornerstone of the treatment of polymyalgia rheumatica (PMR) and giant cell arteritis (GCA), but they are associated with several adverse events (AEs).
BMJ8d
POS0534 EFFICACY OF TELITACICEPT IN THE TREATMENT OF LUPUS NEPHRITIS: A 52-WEEK, MULTICENTER OBSERVATIONAL STUDY
1 University of Science and Technology of China, Rheumatology and Immunology, Hefei, China 2 Bengbu Medical University, Rheumatology and Immunology, Bengbu, China Background: The past decade has ...
BMJ9d
LBA0001 EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH GIANT CELL ARTERITIS (SELECT-GCA): A DOUBLE-BLIND, RANDOMIZED CONTROLLED PHASE 3 TRIAL
11 University of Pennsylvania, Division of Epidemiology, Department of Biostatistics, Epidemiology, and Informatics, Philadelphia, PA, United States of America 12 University of Pennsylvania, Division ...
BMJ9d
Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis
Objectives Evaluation of rituximab and glucocorticoids as therapy to induce remission after relapse in ANCA-associated vasculitis (AAV) in a prospective observational cohort of patients enrolled into ...
BMJ10d
AB0053 BERGENIN, ACTING AS AN AGONIST OF SIRT1, REDUCE SERUM URATE IN MICE THROUGH THE UPREGULATION OF ABCG2
Background: About 20% of individuals in the USA have asymptomatic hyperuricaemia [1]. However, Urate-lowering therapy in asymptomatic hyperuricaemia condition is still controversial considering the ...
BMJ11d
It is time to rethink juvenile idiopathic arthritis classification and nomenclature
Correspondence to Alberto Martini, University of Genoa, Pediatria II, Istituto G Gaslini, Largo Gaslini 5, Genova 16147, Italy; albertomartini{at}ospedale-gaslini.ge.it Juvenile idiopathic arthritis ...
BMJ11d
OP0221 LBL-047, A NOVEL AFUCOSYLATED ANTI-BDCA2/TACI FUSION PROTEIN WITH YTE MUTATION, INHIBITS THE FUNCTIONS OF BOTH pDCs AND B CELLS
Background: Both plasmacytoid dendritic cells (pDCs) and B cells play pivotal roles in various autoimmune diseases, such as systemic lupus erythematosus (SLE), systemic sclerosis, and rheumatoid ...